Observational studyAdvances in therapy2026
Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry.
Observational study in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04287621 (Registry of Asthma Patients Initiating DUPIXENT®), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Registry of Asthma Patients Initiating DUPIXENT® (RAPID)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionCoexisting type 2 inflammatory diseases such as allergic rhinitis (AR), atopic dermatitis (AD), chronic rhinosinusitis (CRS) and/or nasal polyposis (NP), eosinophilic esophagitis (EoE), and urticaria are common in asthma. RAPID (NCT04287621), a global prospective registry, aimed to characterize patients with asthma initiating dupilumab in a real-world clinical setting. This analysis investigated the prevalence of coexisting type 2 inflammatory diseases in these patients.
methodsPatients aged ≥ 12 years initiating dupilumab for asthma (primary indication) according to country-specific prescribing information were enrolled in RAPID. Patients had regular assessments at 1 month and thereafter every 3 months for up to 3 years, per standard of care across study sites.
resultsAt the time of analysis, 205 patients were enrolled. Mean age of patients (stratified by type 2 coexisting disease) ranged from 42.3 to 57.3 years and mean body mass index from 29.9 to 31.8 kg/m
conclusionThis analysis from the RAPID registry shows that type 2 coexisting diseases are highly prevalent in patients with asthma initiating dupilumab in a clinical practice setting and highlights the importance of properly assessing patients to improve patient care.
trial registrationClinicalTrials.gov: NCT04287621.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.